ReviewMolecular biology reports2026
Liquid-liquid phase separation in cancer: oncogenic roles, therapeutic potential, and epigenetic regulation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Abnormal phase separation, especially liquid-liquid phase separation (LLPS), drives disease progression by assembling membraneless organelles and biomolecular condensates and further perturbing key cellular processes. LLPS has garnered increasing attention for its application prospects in cancer treatment. A series of strategies, including the modulation of protein concentration, the regulation of post-translational modifications (PTMs), and the development of small molecules that directly interact with biomolecular condensates, hold significant promise for novel anticancer therapies. This review summarizes the newly discovered roles and mechanisms of dysregulated LLPS in different types of cancer, focusing on transcriptional condensates, signaling and stress condensates, DNA damage response, and oncogenic fusion proteins. Epigenetic mechanisms underlying LLPS dysregulation in cancer, and fresh findings in LLPS-based anticancer strategies are also reviewed. In summary, unraveling the oncogenic roles, therapeutic potentials, and epigenetic regulatory mechanisms of liquid-liquid phase separation will help develop novel strategies for cancer control and for overcoming drug resistance.
Indexed as
Identifiers
42033523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.